الفهرس 
Cancer disease
Mobilization of stem cellsOnly 14 pages are availabe for public view
 |  | from | 193 |  |  |
| | | from | 193 | | |
Abstract
Conventional treatment of cancer by chemotherapy and radiotherapy are used, however, they have severe adverse effects on the vital organs. Cancer immunotherapies by adoptive cell therapy is one of the successful options for treatment of cancer with low side effects, however, it required preconditioning of the host with a lymphodepletion regimen with chemotherapy, to modulate the host’s immune system. The current study aimed to determine the anti-tumor efficacy of co-treatment of CTX- preconditioning EAC-bearing mice with G-CSF or adoptively transferred T cells and bone marrow either harvested from naïve mice or EAC-bearing mice. Eighty naïve female mice (CD1) were IP injected with 2.5 × 105 EAC cells/mouse (n=10/group) including control naïve mice group. On day 8, EAC-bearing mice were intraperitoneally injected with or without CTX (4 mg/mouse). On day 9, EAC-bearing mice that treated with CTX were administered with nBM, tBM, nSP, tSP or G-CSF. On day 10 and 13, all mice were vaccinated with tumor lysate (100 µg/mouse) except naïve and EAC group. CTX alone was used as positive control in addition to negative control that treated with saline. Tumor growth, hematological analyses, biochemical assays, and immunological investigations were carried out. Proceeding to the scarifying, blood samples were collected from retro-orbital plexus for using heparinized micro hematocrit tubes. Combination of chemotherapy (CTX) with immunotherapy followed by vaccination considers as a potent antitumor therapy providing more efficacious antitumor responses. This will provide a useful foundation for a rationale design of anti-cancer immunotherapy regimens by combining lymphodepletion, with BM cells or G-CSF treatment repopulating capacity of cells in the expanded marrow cells, homing of the mobilized cells in the systemic circulation, and facilitating the strategic development of chemoimmunotherapy treatment regimens to maximize tumor regression and the antitumor immune response for the long-term clinical benefit of cancer patients. This combined therapy was strong enough to generate tumor-free mice in the EAC model and immunosuppressive networks.